An Impella update, another TAVI vs SAVR trial, two studies on angina and PCI, another null substudy from REVIVED-BCIS, and semaglutide are the topics John Mandrola, MD, covers in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Impella Update

• CHRIP BCIS 3 https://classic.clinicaltrials.gov/ct2/show/NCT05003817
• Danger-Shock Podcast https://www.medscape.com/viewarticle/1000675

II. TAVI vs SAVR

• Notion 2 Trial EHJ https://doi.org/10.1093/eurheartj/ehae331
• DEDICATE-DZHK6

III. Angina and PCI

• Orbita 2 Sub-analysis
• Orbita Star https://www.jacc.org/doi/10.1016/j.jacc.2024.04.001

IV. Complete Revascularization

• Main REVIVED trial https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
• JACC Substudy https://www.jacc.org/doi/10.1016/j.jacc.2024.04.043

V. Semaglutide

Semaglutide CV Benefits Irrespective of Weight Loss: 4-Year SELECT Data

https://www.medscape.com/viewarticle/semaglutide-cv-benefits-irrespective-weight-loss-4-year-2024a100095z

• Nature Med substudy https://www.nature.com/articles/s41591-024-02996-7
• SELECT Main paper https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]